Clarametyx Biosciences Announces $33M Series A Financing to Advance Anti-Biofilm Biologics for Serious Bacterial Infections
(“Clarametyx”), a clinical stage company developing targeted, immune-enabling biologic therapies to counter persistent infections associated with biofilms, today announced the successful completion of a $33 million Series A round.
- (“Clarametyx”), a clinical stage company developing targeted, immune-enabling biologic therapies to counter persistent infections associated with biofilms, today announced the successful completion of a $33 million Series A round.
- Clarametyx was launched in 2020 to advance a novel, immune-enabling antibody technology licensed from Nationwide Children’s Hospital.
- The company is evaluating its anti-biofilm technology in both therapeutic and preventive settings to address the global challenge of persistent bacterial infection and antibiotic resistance.
- “We graciously welcome our new investors and appreciate the continued commitment of our existing investors.